Condition
Renal Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 53 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
53 shownSL-28 for Advanced Solid TumoursNCT07341737 · 2026-08-14
RECRUITINGRegistry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image GuidanceNCT07636148 · 2026-07-01
RECRUITINGResearch of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic CancersNCT06967961 · 2025-07-23
RECRUITINGOccupational Situation and Return to Work of Urological PatientsNCT07088536 · 2025-07-21
RECRUITINGIrreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)NCT07782164 · 2025-04-18
RECRUITINGDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsNCT06239194 · 2024-06-12
RECRUITING64Cu-GRIP B in Patients With Advanced MalignanciesNCT05888532 · 2023-05-25
RECRUITINGVideo Education With Result Dependent dIsclosureNCT05225428 · 2022-08-04
RECRUITINGcfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseNCT05366881 · 2022-05-03
RECRUITINGThe Man Van ProjectNCT06357416 · 2022-04-13
RECRUITINGImpact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab MonotherapyNCT04605146 · 2021-05-05
RECRUITINGStereotactic Magnetic Resonance Guided Radiation TherapyNCT04115254 · 2019-10-22
RECRUITINGPredictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsNCT03787056 · 2018-12-04
RECRUITINGTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid TumorsNCT03755739 · 2018-11-01
RECRUITINGAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsNCT03175224 · 2017-09-27
RECRUITINGA Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) CancerNCT07610083 · 2026-10-01
NOT_YET_RECRUITINGHead-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewNCT07307157 · 2025-06-12
ENROLLING_BY_INVITATIONComparison Between HUGO RAS Robotic Platform and Da Vinci Robotic PlatformNCT06844513 · 2025-03-31
NOT_YET_RECRUITINGHPI Effect in Robotic Urological Surgery on AKINCT06051162 · 2023-11-07
COMPLETEDA Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNCT05873686 · 2023-10-26
ACTIVE_NOT_RECRUITINGRobot-assisted Urological Surgeries Using the MicroHand S RobotNCT05462392 · 2022-07-28
UNKNOWNExploratory Interventional Study of Prognostic Serum Biomarkers of Cancer ProgressionNCT05426317 · 2022-02-10
UNKNOWNMicrobiome Immunotherapy Toxicity and Response EvaluationNCT04107168 · 2020-07-08
UNKNOWNStudy With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA MarkerNCT03927573 · 2019-04-15
TERMINATEDMRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the TumourNCT03934827 · 2019-04-10
UNKNOWN9-ING-41 in Patients With Advanced CancersNCT03678883 · 2019-01-04
ACTIVE_NOT_RECRUITINGA Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsNCT03693014 · 2018-10-01
ACTIVE_NOT_RECRUITINGStudy of Nivolumab for Advanced Cancers in IndiaNCT03444766 · 2018-03-06
COMPLETEDA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsNCT03289962 · 2017-12-21
COMPLETEDPreliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal CancerNCT03073395 · 2017-07-21
COMPLETEDPhase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.NCT02947165 · 2017-04-25
COMPLETEDA Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersNCT02643303 · 2016-12-28
COMPLETEDMEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsNCT02669914 · 2016-09-12
TERMINATEDStudy of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer PatientsNCT02946671 · 2016-03-01
COMPLETEDDecipher Genomics Resource for Intelligent DiscoveryNCT02609269 · 2015-10-01
ENROLLING_BY_INVITATIONFeasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral SclerosisNCT02457715 · 2015-07-01
COMPLETEDPillars4Life TrialNCT02465892 · 2015-05-01
COMPLETEDT Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveNCT02153905 · 2014-07-03
TERMINATEDProspective Analysis of Robot-Assisted SurgeryNCT02292914 · 2014-03-10
UNKNOWNT Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveNCT02111850 · 2014-02-07
COMPLETEDEffect of Neuromuscular Block and Arterial PCO2 on Surgical Rating Scale (SRS), Following Reversal With SugammadexNCT01968447 · 2014-02-01
COMPLETEDLow Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal CancerNCT01650350 · 2012-11-01
TERMINATEDAssessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaNCT01444456 · 2011-10-01
COMPLETEDCancer in Patients With Gabapentin (GPRD)NCT01236053 · 2010-06-01
COMPLETEDA Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal CancersNCT01086696 · 2010-03-09
TERMINATEDGabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)NCT01138124 · 2010-03-01
COMPLETEDStudy of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumNCT00896454 · 2009-11-16
COMPLETEDStudy of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung CancersNCT01005797 · 2009-11-01
COMPLETEDMechanisms of Anti-VEGF Induced HypertensionNCT02156310 · 2009-01-01
COMPLETEDPhase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaNCT00531284 · 2007-09-01
COMPLETEDA Study of ZYC300 Administered With Cyclophosphamide Pre-DosingNCT00381173 · 2006-11-01
COMPLETEDA Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesNCT00441337 · 2006-08-01
COMPLETEDSpectroscopy With Surface Coils and DecouplingNCT00581815 · 1997-02-01
COMPLETEDCommon interventions
AldesleukinDRUG2AtezolizumabDRUG2CyclophosphamideDRUG2DurvalumabDRUG2FludarabineDRUG2Gabapentin prescriptionsDRUG2NivolumabDRUG2TremelimumabDRUG2[68Ga]P16-093DRUG11H Spectroscopy at 1.5T and 3TDEVICE19-ING-41DRUG1Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)BIOLOGICAL1Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)BIOLOGICAL1APL-101 Oral CapsulesDRUG1Autogene cevumeranDRUG1BevacizumabDRUG1Blood drawsOTHER1Blood sampleOTHER1BP management with HPI guidanceDEVICE1Carboplatin.DRUG1CarfilzomibDRUG1Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapyDRUG1Conventional SurgeryPROCEDURE1Copper-64 labeled Granzyme B (64Cu-GRIP B)DRUG1Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)DRUG1
Leading sponsors
Amgen
3
National Cancer Institute (NCI)
3
Bristol-Myers Squibb
2
Dana-Farber Cancer Institute
2
Duke University
2
GlaxoSmithKline
2
Hospices Civils de Lyon
2
Memorial Sloan Kettering Cancer Center
2
Actuate Therapeutics Inc.
1
Adela, Inc
1
Amsterdam UMC, location VUmc
1
Apollomics Inc.
1
Arduino Mangoni
1
AvenCell Europe GmbH
1
Brown University
1
Trial status mix
COMPLETED21
RECRUITING15
TERMINATED5
UNKNOWN5
ACTIVE_NOT_RECRUITING3
ENROLLING_BY_INVITATION2
NOT_YET_RECRUITING2
Phase mix
PHASE118
PHASE214
NA13
EARLY_PHASE11
PHASE31
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.